1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy, ...
1. 37% of study patients had an objective response to treatment with atezolizumab. 2. Median progression-free survival was 20.8 months. ...
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients ...
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients ...
1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...
Click to read this study in The Lancet Oncology.
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to ...
